Paclitaxel-coated balloons and stents for the treatment of peripheral artery disease: proceedings from the Cardiovascular Research Technologies (CRT) 2019 Town Hall
Eurointervention 2019; publish-ahead-of-print Jun 2019. DOI: 10.4244/EIJY19M06_1
Kazuhiro Dan 1, MD, PhD; Hector M. Garcia-Garcia 1, MD, PhD; Alexandre Hideo-Kajita 1, MD; Cheng Zhang 1, PhD; Jason P. Wermers 1, BSc; Paul Kolm 1, PhD; Rebecca Torguson 1, MPH; Ron Waksman 1, MD
1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington DC, USA
Drug-coated balloons (DCB) and stents with paclitaxel were introduced to treat superficial femoropopliteal artery (SFA) lesions in patients with claudication and/or critical limb ischaemia. Randomised controlled trials (RCTs) demonstrated reduction of restenosis and need for revascularisation for DCB in comparison with plain balloons and bare metal stents and were approved for marketing use in the USA by the Food and Drug Administration (FDA) in 2012. Specifically, multiple RCTs and registries evaluating the treatment of the SFA lesions in patients with claudication have shown the effectiveness of paclitaxel drug-coated balloons (P-DCB) and paclitaxel drug-eluting stents (P-DES). However, there have been conflicting ...